JP2024530315A - Bcl-2阻害剤の固体形態、それらの調製方法及び使用方法 - Google Patents

Bcl-2阻害剤の固体形態、それらの調製方法及び使用方法 Download PDF

Info

Publication number
JP2024530315A
JP2024530315A JP2024513277A JP2024513277A JP2024530315A JP 2024530315 A JP2024530315 A JP 2024530315A JP 2024513277 A JP2024513277 A JP 2024513277A JP 2024513277 A JP2024513277 A JP 2024513277A JP 2024530315 A JP2024530315 A JP 2024530315A
Authority
JP
Japan
Prior art keywords
crystalline form
compound
ray powder
powder diffraction
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530315A5 (cg-RX-API-DMAC7.html
Inventor
ユ、デシェン
シ、ゴォンイン
シュエ、ハイ
グオ、ユンハン
Original Assignee
ベイジーン スウィッツァーランド ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベイジーン スウィッツァーランド ゲーエムベーハー filed Critical ベイジーン スウィッツァーランド ゲーエムベーハー
Publication of JP2024530315A publication Critical patent/JP2024530315A/ja
Publication of JP2024530315A5 publication Critical patent/JP2024530315A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024513277A 2021-08-31 2022-08-31 Bcl-2阻害剤の固体形態、それらの調製方法及び使用方法 Pending JP2024530315A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021115718 2021-08-31
CNPCT/CN2021/115718 2021-08-31
PCT/CN2022/116084 WO2023030363A1 (en) 2021-08-31 2022-08-31 Solid forms of bcl-2 inhibitors, method of preparation, and use thereof

Publications (2)

Publication Number Publication Date
JP2024530315A true JP2024530315A (ja) 2024-08-16
JP2024530315A5 JP2024530315A5 (cg-RX-API-DMAC7.html) 2025-09-03

Family

ID=85410866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513277A Pending JP2024530315A (ja) 2021-08-31 2022-08-31 Bcl-2阻害剤の固体形態、それらの調製方法及び使用方法

Country Status (10)

Country Link
US (1) US20240317743A1 (cg-RX-API-DMAC7.html)
EP (1) EP4396180A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024530315A (cg-RX-API-DMAC7.html)
KR (1) KR20240054327A (cg-RX-API-DMAC7.html)
CN (1) CN118215660A (cg-RX-API-DMAC7.html)
AU (1) AU2022336557A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230314A1 (cg-RX-API-DMAC7.html)
IL (1) IL311106A (cg-RX-API-DMAC7.html)
MX (1) MX2024002465A (cg-RX-API-DMAC7.html)
WO (1) WO2023030363A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116969937B (zh) 2020-04-15 2026-03-24 百济神州(苏州)生物科技有限公司 Bcl-2抑制剂
TW202604488A (zh) 2024-06-26 2026-02-01 瑞士商百濟神州I有限責任公司 包含索托克拉固體分散體之醫藥調配物及其製備方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521138A (ja) * 2018-04-29 2021-08-26 ベイジーン リミテッド Bcl−2阻害剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2546294T7 (es) * 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
KR101762724B1 (ko) * 2011-01-25 2017-07-28 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521138A (ja) * 2018-04-29 2021-08-26 ベイジーン リミテッド Bcl−2阻害剤

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
C.G.WERMUTH編, 最新 創薬化学 下巻, JPN6014029314, 1999, pages 347 - 365, ISSN: 0005866645 *
CAIRA, M.R.: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, JPN6014016881, 1998, pages 163 - 208, ISSN: 0005866642 *
化学実験操作法 上巻, JPN6010029432, 1963, pages 371 - 399, ISSN: 0005866643 *
医薬品の残留溶媒ガイドラインについて, JPN6023047248, 1998, ISSN: 0005866646 *
平山令明, 有機化合物結晶作製ハンドブック, JPN6014022315, 2008, pages 10 - 11, ISSN: 0005866641 *
橋田 充, 経口投与製剤の設計と評価, JPN6008031302, 10 February 1995 (1995-02-10), pages 76 - 79, ISSN: 0005866644 *

Also Published As

Publication number Publication date
CA3230314A1 (en) 2023-03-09
US20240317743A1 (en) 2024-09-26
WO2023030363A1 (en) 2023-03-09
TW202328125A (zh) 2023-07-16
EP4396180A4 (en) 2025-07-09
CN118215660A (zh) 2024-06-18
MX2024002465A (es) 2024-04-29
EP4396180A1 (en) 2024-07-10
AU2022336557A1 (en) 2024-03-21
IL311106A (en) 2024-04-01
KR20240054327A (ko) 2024-04-25

Similar Documents

Publication Publication Date Title
KR20260041111A (ko) 아다그라시브 염의 결정질 형태
TWI526440B (zh) 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{(6-[4-(4-乙基-六氫吡-1-基)-苯胺基]-吡啶-4-基}-1-甲基尿素之結晶型及其鹽
KR102618114B1 (ko) 이브루티닙과 카복실산의 공결정체
US20140343087A1 (en) Crystalline Forms of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP2970123B2 (en) Crystalline dihydrochloride hydrate salt of omecamtiv mecarbil and process for its preparation
JP7314319B2 (ja) Cdk9阻害剤の結晶多形体及びその製造方法と用途
EP3205653B1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
CN108779126A (zh) 2-[(2s)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物的结晶形式
JP2015522037A (ja) ベムラフェニブコリン塩の固体形態
US20240317743A1 (en) Solid Forms of BCL-2 Inhibitors, Method of Preparation, and Use Thereof
ES2814499T3 (es) Formas en estado sólido de sales de Nilotinib
JP2026041824A (ja) テガビビントの結晶形態、調製方法、及びその使用
JP2016512518A (ja) ベムラフェニブ塩酸塩の固体形態
US20190016718A1 (en) Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof
CA3041134A1 (en) Novel salts of nilotinib and crystalline forms thereof
US20220002302A1 (en) Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
CN114026088A (zh) Jak2抑制剂的结晶形式
JP6656505B2 (ja) オービットアジン−フマル酸塩、水和物、結晶形及びその調製方法
KR20060080817A (ko) 시부트라민의 디카복실산염
HK40106793A (en) Solid forms of bcl-2 inhibitors, method of preparation, and use thereof
WO2022224269A1 (en) Co-crystals, salts and solid forms of niraparib
TWI846516B (zh) Cdk9抑制劑的多晶型物及其製法和用途
EP3517529B1 (en) Salt of quinazoline derivative, preparation method therefor and application thereof
KR20240146734A (ko) 피마살탄의 신규 염 및 이의 제조방법
HK40111611A (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250106

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260525